Home
Learn More
Features & Pricing
Success Stories
Contact Us
Search Archives
PRWeb Direct
Submit Release
October 10, 2008
 
Industry Categories  
News by Country  
News by MSA  
Today's News  
Browse by Day  
PR Trackbacks™  
Featured Videos  
ViewNews™  
eBook Digests  
RSS  
PRWeb, a leader in online news and press release distribution, has been used by more than 40,000 organizations of all sizes to increase the visibility of their news, improve their search engine rankings and drive traffic to their Web site.
 
All Press Releases for April 14, 2005 Subscribe to this News Feed    
 

Parker & Waichman, LLP Urges Current and Former Bextra and Celebrex Users to Explore Legal Options

Parker & Waichman, LLP Continues to Offer Free Bextra and Celebrex Legal Case Evaluations at www.bextralegalhelp.com and celebrexlawyernetwork.com. Significant number of injured victims continue to contact firm.

NEW YORK (PRWEB) April 14, 2005 -- Parker & Waichman, LLP (www.yourlawyer.com) has been contacted by numerous current and former Bextra users who believe they were injured as a result of using the drug. Parker & Waichman, LLP continues to evaluate cases and consult with prospective clients who have experienced heart attacks and strokes as well as those who have been diagnosed with Stevens Johnson Syndrome and Toxic Epidermal Necrolysis during the use of Bextra.

Parker & Waichman, LLP and Seeger Weiss LLP filed the first lawsuit in the United States in 2004 against Pfizer claiming their clients sustained injuries and resulting death as a result of ingestion of the drug Bextra.

Parker & Waichman, LLP has also received a significant amount of inquiries from patients who suffered heart attacks and strokes while using Celebrex. Both Bextra and Celebrex patients can receive a free case evaluation by visiting www.bextralegalhelp.com and www.celebrexlawyernetwork.com.

Based on the number of Celebrex inquiries and the research data available, Parker & Waichman, LLP supports Public Citizens view that Celebrex should also be removed from the market. Parker & Waichman, LLP believes that the failure to remove Celebrex from the market puts millions of people at an unnecessary risk.

An unpublished study finished in 2000 indicated increased cardiac risks associated with Celebrex. A more recent study sponsored by the National Cancer Institute discovered that Celebrexs risk of causing a major cardiovascular event was two-and-a-half times greater than that for people taking a placebo. In 2004, almost twice as many prescriptions were written for Celebrex as for Bextra -- 23.9 million prescriptions compared to 12.9 million.

"The removal of Bextra is a step in the right direction but we cannot ignore the high rate of serious side effects associated with Celebrex," commented Jerrold S. Parker, one of the founding partners of Parker & Waichman, LLP. "We continue to believe that Celebrex is a dangerous drug that is no more effective in treating pain and no better tolerated than traditional NSAIDS. We will continue to represent victims of all COX-2 drugs whose lives have been impaired or lost." For more information on Celebrex, please visit www.yourlawyer.com/practice/overview.htm?topic=Celebrex. For more information on Bextra please www.yourlawyer.com/practice/overview.htm?topic=Bextra

For more information on Parker & Waichman, LLP please visit: (http://www.yourlawyer.com) or call 1-800-LAW-INFO (1-800-529-4636). For more information on Public Citizen please visit www.worstpills.org.

Contact:
Parker & Waichman, LLP
David Krangle, Esq.
(800) LAW-INFO (800-529-4636) (toll free)
dkrangle@yourlawyer.com
http://www.yourlawyer.com

###

Technorati Tags

Bookmark -  Del.icio.us | Digg | Furl It | Spurl | RawSugar | Simpy | Shadows | Blink It | My Web


OPTIONS
Printer Friendly Version
Download PDF Version
Download Reader Version
Email this story to a colleague
CONTACT INFORMATION
David Krangle
Parker & Waichman, LLP
516-466-6500
Email us Here
ATTACHED FILES

There are no multimedia files attached to this release. If this is your release, you may add images or other multimedia files through your PRWeb News Management Console.

ABOUT PRESS RELEASES
If you have any questions regarding information in these press releases please contact the company listed in the press release. Please do not contact PRWeb. We will be unable to assist you with your inquiry. PRWeb disclaims any content contained in these release. Our complete disclaimer appears here.
 
Disclaimer: If you have any questions regarding information in these press releases please contact the company listed in the press release.
Please do not contact PRWeb®. We will be unable to assist you with your inquiry.
PRWeb® disclaims any content contained in these releases. Our complete disclaimer appears here.

© Copyright 1997-2008, Vocus PRW Holdings, LLC.
Vocus, PRWeb and Publicity Wire are trademarks or registered trademarks of Vocus, Inc. or Vocus PRW Holdings, LLC.

Terms of Service | Privacy Policy | Copyright